News

Efforts to reduce outlays are generating initiatives to better manage the care for some 10 million dual eligibles.

A study from PwC indicates what lies ahead for the healthcare industry in 2013.

Asthma medications for children must match a child's ability to understand and control treatment of symptoms.

As the motivation for implementing health exchange increases, some states have made little progress.

Private insurers have created novel incentive programs this year to reinforce the practice of primary care.

Medicaid populations might soon be facing additional problems in accessing care

More employers are interested in exploring direct contracting arrangements with providers, according to healthcare experts.

The contraceptive mandate stoked the legal fire of religious groups.

Narrow, high performance networks are making a comeback.

FDA has approved mirabegron (Myrbetriq, Astellas Pharma US, Inc.) to treat adults with overactive bladder, a condition in which the bladder muscle cannot be controlled, squeezes too often, or squeezes without warning.

Everyone has their take on the Supreme Court ruling, but it's time for the industry to roll up its sleeves and get back to work.

In a complex decision, a slim majority of the Supreme Court upheld the constitutionality of the Affordable Care Act.

FDA has approved lorcaserin (Belviq, Arena Pharmaceuticals and Eisai) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients who are overweight or obese and have at least 1 weight-related comorbid condition. It is the first prescription weight-loss treatment approved by FDA in 13 years.

Independence Blue Cross is prepared to capitalize on the opportunity

While many awaited the most significant ruling in healthcare history, Medicaid plans remained optimistic that coverage expansion would continue. But there's a caveat.

FDA issued a complete response letter for a New Drug Application for apixaban (Eliquis, Bristol-Myers Squibb) for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

FDA issued a complete response letter regarding a supplemental New Drug Application for rivaroxaban (Xarelto, Janssen Research & Development) for the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome.

The Academy of Managed Care Pharmacy strongly favors the revisions of the Prescription Drug User Fee Act (PDUFA) that the US House of Representatives and the US Senate conference committee negotiated earlier this week and the House passed by voice vote on Wednesday.

Label prescribing information for dabigatran (Pradaxa, Boehringer Ingelheim) capsules has been updated to affirm that the 150-mg twice-daily dose is superior to warfarin in reducing ischemic and hemorrhagic strokes in patients with nonvalvular atrial fibrillation.

Injections of methotrexate were not superior to oral therapy in long-term treatment of patients with juvenile idiopathic arthritis, according to a new study, published in the May 30 online edition of Arthritis Care & Research.

A combination of 2 diabetes drugs, metformin and rosiglitazone (Avandia, GlaxoSmithKline), was more effective in treating youth with recent-onset type 2 diabetes than metformin alone, a study funded by the National Institutes of Health has found.

House and Senate leaders announced final agreement June 18 on legislation that authorizes industry user fees to support FDA regulatory programs.

Republicans in the House of Representatives have published a report blaming the current increase in drug shortages mostly on FDA under the current administrator.

FDA has approved the first combination vaccination for use in children aged 6 weeks through 18 months for the prevention of invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenza type b, according to an FDA statement.

As the Supreme Court debates the constitutionality of the Patient Protection and Affordable Care Act, some states are taking a wait-and-see attitude on health insurance exchange implementation, while others are forging ahead. Meanwhile, private exchanges are gaining some traction.

Approximately half of drug labels don’t have information on the medication’s safety and proper dosing in children, revealing an overall lack of study of children’s drug therapies, according to a study from FDA researchers.

A substantial proportion of patients initiating an oral hypoglycemic drug do not receive the recommended therapy. The potential savings from improved adherence to the recommendations could top $420 million annually.

People with private individual health insurance will save between $280 to $589 annually via health exchanges under the Patient Protection and Affordable Care Act. But who will pay for those savings?